Sharmilan Thanendrarajan, MD
Hematology & Oncology · Little Rock, ARNPI 1689097313
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,293 of the $4,981 with a category attached, or 86.2%. Sanofi accounts for 72.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $2,885 and has fallen 93.1% since, to $199 in 2025. That places this record below the midpoint for hematology & oncology clinicians in AR, where the typical reported total is $4,667.
Across 12 payments — averaging $415.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$4K
- Janssen Scientific Affairs, LLC$1K
- Johnson & Johnson$123
- Astellas Pharma US Inc$70
- Janssen Research & Development, LLC$59
- Beone Medicines USA, Inc.$15
- plus $12 from 1 others
Across 3 payments — averaging $10,793 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$22K
- E.r. Squibb & Sons, L.L.C.$6K
- Novartis$5K
What the payments were for
- Consulting fees$4,29386%
- Food & beverage$50710%
- Education$1814%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 5 | $3,612 |
| Janssen Scientific Affairs, LLC | 1 | $1,090 |
| Johnson & Johnson | 2 | $123 |
| Astellas Pharma US Inc | 1 | $70 |
| Janssen Research & Development, LLC | 1 | $59 |
| Beone Medicines USA, Inc. | 1 | $15 |
| Acrotech Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,981 in reported general payments places this provider in the 50th percentile of 92 hematology & oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 40 | $913,277 |
| RevlimidLenalidomide | 57 | $894,716 |
| Lenalidomide | 68 | $765,354 |
| Morphine Sulfate | 20 | $16 |
| Lorazepam | 22 | $14 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Little Rock
- Frits van RheeLittle Rock$218K
- Appalanaidu SasapuLittle Rock$63K
- Peter EmanuelLittle Rock$53K
- Brad BaltzLittle Rock$25K
- Carolina SchinkeLittle Rock$23K
- Pooja MotwaniLittle Rock$21K
- Naveen YarlagaddaLittle Rock$18K
- Joseph BeckLittle Rock$16K
- Konstantinos ArnaoutakisLittle Rock$12K
- Abhijit GodboleLittle Rock$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.